



Approved for use through 07/31/2012. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/554,732-Conf. #9693
--------------------	------------------------

Filing Date	January 5, 2007
-------------	-----------------

First Named Inventor	Christian Hubschwerlen
----------------------	------------------------

Art Unit	4161
----------	------

Examiner Name	P. E. Zarek
---------------	-------------

Attorney Docket Number	64391(41925)
------------------------	--------------

U.S. PATENT DOCUMENTS[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	WO-03/031441-A1	04-17-2003	Morphochem AG Aktiengesellschaft Für Kombinatorische Chemie		
	BB	WO-03/031443-A1	04-17-2003	Morphochem AG Aktiengesellschaft Für Kombinatorische Chemie		
	BC	WO-03/032962-A2	04-24-2003	Morphochem AG Aktiengesellschaft Für Kombinatorische Chemie		
	BD	WO-2005/058888-A2	06-30-2005	Morphochem AG		
	BE	WO-2005/023801-A1	03-17-2005	Morphochem AG		
	BF	KR-10 2000 00673606	11-15-2000	Korea Institute of Science and Technology		✓
	BG	WO 01/46164	06-28-2001	Ortho-McNeil Pharmaceutical, Inc.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/554,732-Conf. #9693
				Filing Date	January 5, 2007
				First Named Inventor	Christian Hubschwerlen
				Art Unit	4161
				Examiner Name	P. E. Zarek
Sheet	2	of	2	Attorney Docket Number	64391(41925)

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	CA	C. Hubschwerlen et al., "Design, Synthesis and Biological Evaluation of Oxazolidinone - Quinolone Hybrids", <i>Bioorganic & Medicinal Chemistry</i> , Vol. 11, pgs. 2313-2319 (2003).		
	CB	C. Hubschwerlen et al., "Structure-Activity Relationship in the Oxazolidinone-Quinolone Hybrid Series: Influence of the Central Spacer on the Antibacterial Activity and the Mode of Action", <i>Bioorganic & Medicinal Chemistry</i> , Vol. 13, pgs. 4229-4233 (2003).		
	CC	Locher et al., "Synthesis and Antibacterial Action of Novel Quinolone-linked Oxazolidinones", 42th ICAAC (2002), poster and abstract F-1317, ICAAC 2002: San Diego, CA, September 27-30, 2002.		
	CD	Hubschwerlen et al., "New Oxazolidinone-Quinolone Hybrids: Synthesis and SAR", 43rd ICAAC (2003), abstract F-2144, Chicago, IL, September 14-17, 2003.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/554,732-Conf. #9693
				Filing Date	January 5, 2007
				First Named Inventor	Christian Hubschwerlen
				Art Unit	4161
				Examiner Name	P. E. Zarek
Sheet	2	of	2	Attorney Docket Number	64391(41925)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	C. Hubschwerlen et al., "Design, Synthesis and Biological Evaluation of Oxazolidinone - Quinolone Hybrids", <i>Bioorganic & Medicinal Chemistry</i> , Vol. 11, pgs. 2313-2319 (2003).	
	CB	C. Hubschwerlen et al., "Structure-Activity Relationship in the Oxazolidinone-Quinolone Hybrid Series: Influence of the Central Spacer on the Antibacterial Activity and the Mode of Action", <i>Bioorganic & Medicinal Chemistry</i> , Vol. 13, pgs. 4229-4233 (2003).	
	CC	Locher et al., "Synthesis and Antibacterial Action of Novel Quinolone-linked Oxazolidinones", 42th ICAAC (2002), poster and abstract F-1317, ICAAC 2002: San Diego, CA, September 27-30, 2002.	
	CD	Hubschwerlen et al., "New Oxazolidinone-Quinolone Hybrids: Synthesis and SAR", 43rd ICAAC (2003), abstract F-2144, Chicago, IL, September 14-17, 2003.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.